scholarly article | Q13442814 |
P356 | DOI | 10.1007/S12031-016-0851-3 |
P698 | PubMed publication ID | 27752929 |
P50 | author | Majid Kheirollahi | Q64794334 |
Fariborz Khorvash | Q82566876 | ||
P2093 | author name string | Naeim Ehtesham | |
P2860 | cites work | Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis | Q21135220 |
MicroRNAs miR-17 and miR-20a inhibit T cell activation genes and are under-expressed in MS whole blood | Q21562182 | ||
Multiple sclerosis: Geoepidemiology, genetics and the environment | Q22252524 | ||
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” | Q22252938 | ||
KEGG: kyoto encyclopedia of genes and genomes | Q24515297 | ||
Regulation of type I interferon responses | Q26853177 | ||
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources | Q27860739 | ||
MicroRNAs: genomics, biogenesis, mechanism, and function | Q27861070 | ||
Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists | Q28131785 | ||
Mechanisms of type-I- and type-II-interferon-mediated signalling | Q28247893 | ||
Circulating microRNAs as biomarkers for disease staging in multiple sclerosis | Q28287246 | ||
MicroRNA-21 promotes Th17 differentiation and mediates experimental autoimmune encephalomyelitis | Q28975627 | ||
Regulation of mRNA translation and stability by microRNAs | Q29547304 | ||
Biomarkers in multiple sclerosis | Q30978587 | ||
Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls | Q33510154 | ||
Unraveling natalizumab effects on deregulated miR-17 expression in CD4+ T cells of patients with relapsing-remitting multiple sclerosis | Q33678267 | ||
Small non-coding RNA signature in multiple sclerosis patients after treatment with interferon-β. | Q33765140 | ||
Beta-interferon for multiple sclerosis | Q33843993 | ||
Inhibition of cell viability by human IFN-β is mediated by microRNA-431. | Q34251002 | ||
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial | Q34611762 | ||
Baseline gene expression signatures in monocytes from multiple sclerosis patients treated with interferon-beta | Q34700070 | ||
Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b | Q34994463 | ||
MicroRNA-572 expression in multiple sclerosis patients with different patterns of clinical progression | Q35599410 | ||
MicroRNAs and STAT interplay. | Q35785559 | ||
Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis | Q35847422 | ||
Multiple sclerosis--the plaque and its pathogenesis | Q36410882 | ||
miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database | Q36434925 | ||
Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis | Q36638670 | ||
MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients | Q37139127 | ||
microRNAs and the immune response | Q37178538 | ||
Predicting responders to therapies for multiple sclerosis | Q37606292 | ||
IFN-beta pharmacogenomics in multiple sclerosis | Q37780222 | ||
Determinants of interferon β efficacy in patients with multiple sclerosis | Q37848651 | ||
The emerging role of p38 mitogen-activated protein kinase in multiple sclerosis and its models. | Q38125129 | ||
Regulation of interferon-dependent mRNA translation of target genes | Q38190098 | ||
miRNA in multiple sclerosis: search for novel biomarkers | Q38447020 | ||
MiR-126: a novel route for natalizumab action? | Q42233577 | ||
Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients. | Q46490039 | ||
miRWalk2.0: a comprehensive atlas of microRNA-target interactions | Q46692723 | ||
MicroRNA expression profiling of esophageal cancer before and after induction chemoradiotherapy | Q47199545 | ||
Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. | Q48301171 | ||
Differential microRNA expression in blood in multiple sclerosis. | Q50901331 | ||
Targeted Stage-Specific Inflammatory microRNA Profiling in Urine During Disease Progression in Experimental Autoimmune Encephalomyelitis: Markers of Disease Progression and Drug Response. | Q53383288 | ||
Identification of short-term pharmacodynamic effects of interferon-beta-1a in multiple sclerosis subjects with broad- based phenotypic profiling. | Q53566540 | ||
Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects. | Q54507185 | ||
IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression. | Q54529253 | ||
Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy | Q84089706 | ||
P433 | issue | 1 | |
P921 | main subject | multiple sclerosis | Q8277 |
pleiotropy | Q1134884 | ||
P304 | page(s) | 16-24 | |
P577 | publication date | 2016-10-17 | |
P1433 | published in | Journal of Molecular Neuroscience | Q15708870 |
P1476 | title | miR-145 and miR20a-5p Potentially Mediate Pleiotropic Effects of Interferon-Beta Through Mitogen-Activated Protein Kinase Signaling Pathway in Multiple Sclerosis Patients | |
P478 | volume | 61 |
Q92355853 | Elevated microRNA-145 inhibits the development of oral squamous cell carcinoma through inactivating ERK/MAPK signaling pathway by down-regulating HOXA1 |
Q89493546 | Environmental Influencers, MicroRNA, and Multiple Sclerosis |
Q92354306 | Precision Medicine in Neurodegenerative Diseases: Some Promising Tips Coming from the microRNAs' World |
Search more.